Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. (AMLX): 5 pipeline candidates · 1 upcoming catalyst · ~23 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
22.7 months
D/E 0.07 · 0% dilution
Lead: Approved
5 candidates
1 upcoming, next in ~105d
2 buys · 17 sells (180d)
A transparent, data-derived signal for Amylyx Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$230.1M
Quarterly Burn
$36.9M
Runway
22.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| AMX0035 | Phase 2 |
| AMX0035 (RELYVRIO / ALBRIOZA) | Approved |
| AMX0114 | Phase 1 |
| amx0318 | Phase 2 |
| avexitide | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
170
Total value held
$1.66B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 16,630,541 | $231.2M |
| perceptive advisors llc | 16,569,764 | $230.3M |
| janus henderson group plc | 9,972,146 | $138.5M |
| blackrock, inc. | 8,828,836 | $122.7M |
| vanguard capital management llc | 8,283,150 | $115.1M |
| commodore capital lp | 5,650,000 | $78.5M |
| adage capital partners gp, l.l.c. | 3,560,764 | $49.5M |
| driehaus capital management llc | 2,987,147 | $41.5M |
| goldman sachs group inc | 2,625,991 | $36.5M |
| state street corp | 2,363,161 | $32.8M |
Showing top 10 of 170 institutional holders of Amylyx Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Amylyx Pharmaceuticals, Inc.'s pipeline?
Amylyx Pharmaceuticals, Inc. (AMLX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Amylyx Pharmaceuticals, Inc.'s lead drug candidate?
Amylyx Pharmaceuticals, Inc.'s most advanced tracked candidate is AMX0035 (Phase 2) for Wolfram Syndrome.
What is Amylyx Pharmaceuticals, Inc.'s next catalyst?
Amylyx Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy a" — expected October 1, 2026.
What is Amylyx Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Amylyx Pharmaceuticals, Inc. has approximately 22.7 months of cash runway.
What is Amylyx Pharmaceuticals, Inc.'s market capitalization?
Amylyx Pharmaceuticals, Inc.'s market capitalization is approximately $1.7B.
Get the full picture on Amylyx Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.